Form 4: Encompass Health CEO Sells 140,000 Shares Under 10b5-1 Plan

Encompass Health Corp's President and CEO, Mark J. Tarr, sold 140,000 shares of common stock on February 11, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Mark J. Tarr, President & CEO and Director of Encompass Health Corp (EHC), reported the sale of 140,000 shares of common stock.
• The transactions occurred on February 11, 2026, and were executed under a Rule 10b5-1(c) plan.
• The shares were sold in multiple transactions at weighted average prices ranging from $108.03 to $113.09 per share.
• Following these transactions, Mark J. Tarr directly beneficially owns 377,070 shares of Encompass Health Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider transaction, likely for diversification or personal liquidity, and not indicative of a change in company fundamentals or management's confidence.

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under a Rule 10b5-1 trading plan, are common for executive compensation and personal financial planning. Such pre-arranged sales typically do not signal a change in management's outlook on the company's future performance or a lack of confidence, as they are scheduled in advance to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders may note the reduction in direct holdings by the CEO, but the execution under a Rule 10b5-1 plan suggests a pre-planned, non-discretionary sale, which typically mitigates concerns about management's view of the company's prospects.

Key Dates

Recommendation

The sale by the President & CEO, Mark J. Tarr, appears to be a pre-planned transaction under a Rule 10b5-1 plan, which is a common practice for executives to manage personal finances and diversify holdings. Such planned sales typically do not reflect a change in the company's fundamental outlook or management's confidence, thus a 'hold' recommendation is appropriate as this event alone does not provide new information to alter an existing investment thesis.

Keywords

Encompass Health, EHC, Insider Sale, Form 4, Mark J. Tarr, CEO, Director, Stock Transaction, Rule 10b5-1